"Having personally been involved in the evaluation of over 30 Phase II trials over my career, none of which ever achieved statistical significance, including many of today's blockbuster biotech products,..."
Prove that any of his 30 phase II trials achieved what he would describe as statistical significance.
"out of here for a while"...? Don't want to post as the good news comes out over the next couple of months? There will be several others " missing in action" as the stock price moves up. Breast,pancreatic and two NSCLC trial results along with potential FDA and partnering news will be welcomed by shareholders.